FOLH1 and cancer: Furthermore, previous studies reported that folate-conjugated delivery platforms could achieve specific delivery of various payloads to PSMA-expressing PCa cells and demonstrated better anti-cancer efficacy in vivo as compared to non-targeted ones [38,42,43,44,45].